---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019706"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:09:17.517851+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program

## Summary
- Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.
- Approximately $500,000 in non-dilutive funding; Phase I award to assess scientific and commercial potential.
- Funds will be used to characterize lead candidate molecules inhibiting the influenza polymerase complex.
- Successful Phase I completion may qualify Cocrystal to apply for a larger Phase II award.
- Company continues to pursue additional non-dilutive government and military funding.

## SEC filing metadata
- accession: 0001493152-25-019706
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315225019706/0001493152-25-019706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315225019706/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019706
- JSON: https://secwatch.observer/filing/0001493152-25-019706.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.